Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma (R)) plus treatment of physician&apos;s choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B)

Sim, Sung Hoon; Kim, Jeong Eun; Kim, Min Hwan; Park, Yeon Hee; Kim, Jee Hyun; Suh, Koung Jin; Koh, Su-Jin; Park, Kyong Hwa; Kang, Myoung Joo; Ahn, Mi Sun; Lee, Kyoung Eun; Kim, Hee -Jun; Ahn, Hee Kyung; Kim, Han Jo; Park, Keon Uk; Byun, Jae Ho; Park, Jin Hyun; Lee, Gyeong-Won; Lee, Keun Seok; Sohn, Joo Hyuk; Jung, Kyung Hae; Park, In Hae

doi:10.1016/j.breast.2022.08.002

YUHSpace

BROWSE

0 373

Cited 0 times in

Cited 3 times in

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma (R)) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B)

Authors: Sim, Sung Hoon ; Kim, Jeong Eun ; Kim, Min Hwan ; Park, Yeon Hee ; Kim, Jee Hyun ; Suh, Koung Jin ; Koh, Su-Jin ; Park, Kyong Hwa ; Kang, Myoung Joo ; Ahn, Mi Sun ; Lee, Kyoung Eun ; Kim, Hee -Jun ; Ahn, Hee Kyung ; Kim, Han Jo ; Park, Keon Uk ; Byun, Jae Ho ; Park, Jin Hyun ; Lee, Gyeong-Won ; Lee, Keun Seok ; Sohn, Joo Hyuk ; Jung, Kyung Hae ; Park, In Hae

Citation: Breast, Vol.65 : 172-178, 2022-10

Journal Title: BREAST

ISSN: 0960-9776

Issue Date: 2022-10

Keywords: HER2 positive ; Metastatic breast cancer ; Trastuzumab biosimilar ; Clinical trial ; ctDNA

Abstract: We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma (R), in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.

DOI: 10.1016/j.breast.2022.08.002

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

Yonsei Authors: Kim, Min Hwan(김민환) https://orcid.org/0000-0002-1595-6342
Sohn, Joo Hyuk(손주혁) https://orcid.org/0000-0002-2303-2764

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/193377

사서에게 알리기

Show full item record Find it @ YMLIB

License

YUHSpace: Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma (R)) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B)

YUHSpace

BROWSE

Browse

Links